Blame me for the FDA decision if you like, but I prefer to talk about the situation now. You know, a company with a very good chance of starting a phase3 trial in Europe and Aus, with very good Phase2 results, with almost zero enterprise value. To me that is a pretty good punt.
Ann: Prana provides regulatory update for PBT2-PBT.AX, page-54
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.04K | 865.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 49239172 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 127041874 | 18 |
View Market Depth
| Last trade - 15.42pm 12/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |